155 related articles for article (PubMed ID: 33738601)
1. Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE.
Fronda M; Doriguzzi Breatta A; Gatti M; Calandri M; Maglia C; Bergamasco L; Righi D; Faletti R; Fonio P
Eur Radiol; 2021 Sep; 31(9):6578-6588. PubMed ID: 33738601
[TBL] [Abstract][Full Text] [Related]
2. Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
Müller L; Hahn F; Jungmann F; Mähringer-Kunz A; Stoehr F; Halfmann MC; Pinto Dos Santos D; Hinrichs J; Auer TA; Düber C; Kloeckner R
Cancer Imaging; 2022 Jan; 22(1):5. PubMed ID: 35016731
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
4. Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models.
Vosshenrich J; Zech CJ; Heye T; Boldanova T; Fucile G; Wieland S; Heim MH; Boll DT
Eur Radiol; 2021 Jun; 31(6):4367-4376. PubMed ID: 33274405
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE.
Hu W; Cao G; Ye S; Xu J; Chen J; Shao G
Medicine (Baltimore); 2023 Jun; 102(24):e34054. PubMed ID: 37327303
[TBL] [Abstract][Full Text] [Related]
6. The Role of Immediate Post-Procedural Cone-Beam Computed Tomography (CBCT) in Predicting the Early Radiologic Response of Hepatocellular Carcinoma (HCC) Nodules to Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE).
Fronda M; Mistretta F; Calandri M; Ciferri F; Nardelli F; Bergamasco L; Fonio P; Doriguzzi Breatta A
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498664
[TBL] [Abstract][Full Text] [Related]
7. Parenchymal Blood Volume Assessed by C-Arm-Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma.
Syha R; Grözinger G; Grosse U; Maurer M; Zender L; Horger M; Nikolaou K; Ketelsen D
Invest Radiol; 2016 Feb; 51(2):121-6. PubMed ID: 26488373
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
[TBL] [Abstract][Full Text] [Related]
9. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
10. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
11. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
[TBL] [Abstract][Full Text] [Related]
12. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Therapeutic Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Based on Pretherapeutic Dynamic CT and Textural Findings.
Park HJ; Kim JH; Choi SY; Lee ES; Park SJ; Byun JY; Choi BI
AJR Am J Roentgenol; 2017 Oct; 209(4):W211-W220. PubMed ID: 28813195
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
[TBL] [Abstract][Full Text] [Related]
15. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings.
Bayle M; Clerc-Urmès I; Ayav A; Bronowicki JP; Petit I; Orry X; Laurent V
Abdom Radiol (NY); 2019 Jan; 44(1):85-94. PubMed ID: 30054686
[TBL] [Abstract][Full Text] [Related]
16. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST.
Liu M; Lin MX; Lu MD; Xu ZF; Zheng KG; Wang W; Kuang M; Zhuang WQ; Xie XY
Eur Radiol; 2015 Aug; 25(8):2502-11. PubMed ID: 25702094
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
[TBL] [Abstract][Full Text] [Related]
18. Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.
Li B; Zhou L; Xu A; Li Q; Xiang H; Huang Y; Peng L; Xiang K; Zhang M; Wang N
Curr Med Imaging; 2022; 18(11):1186-1194. PubMed ID: 35249499
[TBL] [Abstract][Full Text] [Related]
19. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
20. Two-dimensional parametric parenchymal blood flow in transarterial chemoembolisation for hepatocellular carcinoma: perfusion change quantification and tumour response prediction at 3 months post-intervention.
Becker LS; Maschke SK; Dewald CLA; Meine TC; Winther HBM; Kirstein MM; Kloeckner R; Meyer BC; Wacker F; Hinrichs JB
Clin Radiol; 2021 Feb; 76(2):160.e27-160.e33. PubMed ID: 33028487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
